Cantor Fitzgerald Reaffirms Overweight Rating for Jasper Therapeutics (NASDAQ:JSPR)

Cantor Fitzgerald reaffirmed their overweight rating on shares of Jasper Therapeutics (NASDAQ:JSPR) in a research note released on Monday, Benzinga reports.

A number of other research firms also recently issued reports on JSPR. HC Wainwright reissued a buy rating and issued a $65.00 target price on shares of Jasper Therapeutics in a research report on Tuesday, August 13th. Stifel Nicolaus began coverage on Jasper Therapeutics in a research report on Thursday, June 27th. They issued a buy rating and a $86.00 target price for the company. BTIG Research began coverage on Jasper Therapeutics in a research report on Monday, July 8th. They issued a buy rating and a $90.00 target price for the company. Royal Bank of Canada decreased their target price on Jasper Therapeutics from $70.00 to $68.00 and set an outperform rating for the company in a research report on Wednesday, August 14th. Finally, Evercore ISI reissued an outperform rating and issued a $65.00 target price on shares of Jasper Therapeutics in a research report on Monday, August 26th. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of Buy and a consensus target price of $73.00.

Jasper Therapeutics Trading Up 1.8 %

Shares of Jasper Therapeutics stock opened at $20.66 on Monday. The business’s fifty day simple moving average is $19.46 and its 200 day simple moving average is $22.68. The firm has a market capitalization of $311.15 million, a P/E ratio of -3.67 and a beta of 2.22. Jasper Therapeutics has a 12 month low of $4.00 and a 12 month high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.97) EPS for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.12. Analysts predict that Jasper Therapeutics will post -4.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Jasper Therapeutics

Several hedge funds have recently made changes to their positions in JSPR. Ieq Capital LLC purchased a new position in shares of Jasper Therapeutics in the fourth quarter valued at $43,000. Rhumbline Advisers purchased a new position in Jasper Therapeutics during the second quarter worth about $300,000. Virtu Financial LLC purchased a new position in Jasper Therapeutics during the first quarter worth about $306,000. American Century Companies Inc. grew its position in Jasper Therapeutics by 27.1% during the second quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock worth $322,000 after buying an additional 3,032 shares in the last quarter. Finally, Concurrent Investment Advisors LLC purchased a new position in Jasper Therapeutics during the first quarter worth about $599,000. 79.85% of the stock is currently owned by hedge funds and other institutional investors.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.